AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities research analysts at B. Riley issued their FY2022 earnings estimates for AMAG Pharmaceuticals in a research report issued on Tuesday, Zacks Investment Research reports. B. Riley analyst D. Buck anticipates that the specialty pharmaceutical company will post earnings of $1.78 per share for the year. B. Riley currently has a “Hold” rating and a $16.00 target price on the stock.
Several other brokerages also recently commented on AMAG. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Tuesday, October 17th. Morgan Stanley decreased their price target on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, November 3rd. Piper Jaffray Companies reaffirmed a “hold” rating and set a $15.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, January 18th. Finally, Leerink Swann reaffirmed a “market perform” rating on shares of AMAG Pharmaceuticals in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $19.89.
Shares of AMAG Pharmaceuticals (AMAG) traded up $0.65 during mid-day trading on Wednesday, reaching $12.95. 2,352,849 shares of the company’s stock traded hands, compared to its average volume of 888,063. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94. The firm has a market cap of $458.09, a P/E ratio of -2.13 and a beta of 0.79. AMAG Pharmaceuticals has a 52-week low of $11.93 and a 52-week high of $25.20.
Several large investors have recently added to or reduced their stakes in the stock. Systematic Financial Management LP grew its stake in shares of AMAG Pharmaceuticals by 31.9% in the fourth quarter. Systematic Financial Management LP now owns 111,535 shares of the specialty pharmaceutical company’s stock valued at $1,478,000 after buying an additional 26,945 shares in the last quarter. Rhumbline Advisers grew its stake in shares of AMAG Pharmaceuticals by 12.8% in the fourth quarter. Rhumbline Advisers now owns 84,341 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after buying an additional 9,576 shares in the last quarter. Arizona State Retirement System grew its stake in shares of AMAG Pharmaceuticals by 224.9% in the fourth quarter. Arizona State Retirement System now owns 59,455 shares of the specialty pharmaceutical company’s stock valued at $788,000 after buying an additional 41,155 shares in the last quarter. Balter Liquid Alternatives LLC bought a new position in shares of AMAG Pharmaceuticals in the fourth quarter valued at $120,000. Finally, Teacher Retirement System of Texas bought a new position in shares of AMAG Pharmaceuticals in the fourth quarter valued at $162,000.
ILLEGAL ACTIVITY WARNING: “Equities Analysts Offer Predictions for AMAG Pharmaceuticals, Inc.’s FY2022 Earnings (NASDAQ:AMAG)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://ledgergazette.com/2018/02/11/amag-pharmaceuticals-inc-expected-to-earn-fy2022-earnings-of-1-78-per-share-amag.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.